109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
心力衰竭患者应用常规心血管药物联合沙库巴曲缬沙坦钠治疗对心功能改善的定量评估
Authors Liu C, Lai C, Xu M, Wang Y
Received 5 August 2025
Accepted for publication 29 October 2025
Published 10 November 2025 Volume 2025:18 Pages 6847—6857
DOI https://doi.org/10.2147/IJGM.S558534
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Redoy Ranjan
Chengnan Liu, Changchun Lai, Min Xu, Yunxiang Wang
Department of Cardiovascular Medicine, the First People’s Hospital of Yongkang City, Yongkang City, Zhejiang Province, People’s Republic of China
Correspondence: Chengnan Liu, Department of Cardiovascular Medicine, the First People’s Hospital of Yongkang City, No. 599, Jinshan West Road, Yongkang City, Zhejiang Province, 321300, People’s Republic of China, Email 44628807@qq.com
Objective: To explore the effect of conventional cardiology drug therapy combined with sacubitril/valsartan sodium on improving cardiac function in patients with heart failure.
Methods: A retrospective analysis was conducted on data from heart failure patients diagnosed and treated in our hospital between March 2022 and December 2023. Patients were divided into a control group and an experimental group based on treatment methods. The control group received conventional cardiology drug therapy, while the experimental group received conventional cardiology drug therapy combined with sacubitril/valsartan sodium. Cardiac function indicators and related clinical outcomes were compared between the two groups before and after treatment.
Results: The overall clinical efficacy rate in the experimental group was significantly higher than in the control group (P < 0.05). After treatment, the experimental group exhibited higher levels of LVEF, SV, and CO, while LVESD and LVEDD levels were significantly lower compared to the control group (P < 0.05). Levels of NT-proBNP, Hcy, and cTnI in the experimental group were significantly lower than in the control group after treatment (P < 0.05). Additionally, levels of NE, ALD, and AngII in the experimental group were significantly lower than those in the control group post-treatment (P < 0.05). The 6-minute walk test (6 MWT) performance was better in the experimental group, and their MLHFQ (Minnesota Living with Heart Failure Questionnaire) scores were lower than those in the control group (P < 0.05). The incidence of adverse events was similar between the two groups (P > 0.05).
Conclusion: Conventional cardiology drug therapy combined with sacubitril/valsartan sodium significantly improves cardiac function in patients with heart failure. It achieves this by modulating neuroendocrine function, counteracting adverse effects, and promoting the reversal of ventricular remodeling. The treatment also demonstrates good safety, effectively enhancing patients’ exercise capacity and quality of life.
Keywords: heart failure, conventional drug therapy, sacubitril/valsartan sodium, cardiac function, analysis
Department of Cardiovascular Medicine, the First People’s Hospital of Yongkang City, Yongkang City, Zhejiang Province, People’s Republic of China
Correspondence: Chengnan Liu, Department of Cardiovascular Medicine, the First People’s Hospital of Yongkang City, No. 599, Jinshan West Road, Yongkang City, Zhejiang Province, 321300, People’s Republic of China, Email 44628807@qq.com
Objective: To explore the effect of conventional cardiology drug therapy combined with sacubitril/valsartan sodium on improving cardiac function in patients with heart failure.
Methods: A retrospective analysis was conducted on data from heart failure patients diagnosed and treated in our hospital between March 2022 and December 2023. Patients were divided into a control group and an experimental group based on treatment methods. The control group received conventional cardiology drug therapy, while the experimental group received conventional cardiology drug therapy combined with sacubitril/valsartan sodium. Cardiac function indicators and related clinical outcomes were compared between the two groups before and after treatment.
Results: The overall clinical efficacy rate in the experimental group was significantly higher than in the control group (P < 0.05). After treatment, the experimental group exhibited higher levels of LVEF, SV, and CO, while LVESD and LVEDD levels were significantly lower compared to the control group (P < 0.05). Levels of NT-proBNP, Hcy, and cTnI in the experimental group were significantly lower than in the control group after treatment (P < 0.05). Additionally, levels of NE, ALD, and AngII in the experimental group were significantly lower than those in the control group post-treatment (P < 0.05). The 6-minute walk test (6 MWT) performance was better in the experimental group, and their MLHFQ (Minnesota Living with Heart Failure Questionnaire) scores were lower than those in the control group (P < 0.05). The incidence of adverse events was similar between the two groups (P > 0.05).
Conclusion: Conventional cardiology drug therapy combined with sacubitril/valsartan sodium significantly improves cardiac function in patients with heart failure. It achieves this by modulating neuroendocrine function, counteracting adverse effects, and promoting the reversal of ventricular remodeling. The treatment also demonstrates good safety, effectively enhancing patients’ exercise capacity and quality of life.
Keywords: heart failure, conventional drug therapy, sacubitril/valsartan sodium, cardiac function, analysis